Associate
Chartered Patent Attorney
European Patent Attorney
UK Design Attorney
Postgraduate Certificate in Intellectual Property Law, Queen Mary University of London
BSc Biochemistry, University College London
MSc Cellular Therapy from Bench to Market, King’s College London
Thank you
Matt graduated from UCL in 2017 with a bachelor’s degree in Biochemistry. He subsequently obtained a master’s degree entitled ‘Cellular Therapy from Bench to Market’, a program which blended biology and business to explore the science, regulation and routes to market underpinning advanced therapies. His thesis was a business plan to commercialise a stem cell-derived therapy for Parkinson’s disease. Following this, Matt joined the Cell and Gene Therapy Catapult as a laboratory technician gaining experience in ddPCR, cell culture, non-viral gene editing techniques, flow cytometry, as well as upstream and downstream processing of AAV (viral vector) for gene therapy applications
Matt joined Keltie in 2022 following three years training at another leading patent law firm. He qualified as a UK and European Patent Attorney in 2024.
Matt particularly enjoys working closely with clients to understand not only the detail behind their technology, but the business needs behind their intellectual property. He has experience in both drafting and prosecution, advising multinational pharmaceutical clients and early-stage spin-outs in a range of fields including antibodies, cell and gene therapies, non-viral gene editing, MedTech, small molecules, and nanotechnologies.
02.04.2024
Patents, plausibility and data: one year on from G 2/21On 23 March 2023, the European Patent Office (EPO) Enlarged Board of Appeal (EBA) published its decision in case G 2/21, concerning plausibility in patent applications. The decision provided useful guidance on how much data needs to be disclosed in a patent application to overcome objections based on the grounds of lack of inventive step and insufficiency. One year on, we take a look at how the EPO has been applying this standard in the life sciences field.
12.09.2022
The long-term impact of Brexit on trade marks and designsSix years on from the Brexit referendum, we can happily say that the measures put in place for trade marks and designs have been successful in delivering a smooth transition. But IP owners now need to pay attention to upcoming changes to rights of representation, particularly in light of the huge growth in applications at the UK IPO.
OtherLess related knowledge
03.12.2024 - 04.12.2024
SynbiTECH 2024Keltie is proud to sponsor this important event bringing together leaders in engineering biology.
Thank you
